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Lipedema is a chronic progressive disease characterized by abnormal fat distribution resulting in dispropor-
tionate, painful limbs. It almost exclusively affects women, leading to considerable disability, daily function-
ing impairment, and psychosocial distress. Literature shows both scarce and conflicting data regarding its 
prevalence. Lipedema has been considered a rare entity by several authors, though it may be a far more 
frequent condition than thought. Despite the clinical impact on women’s health, lipedema is in fact mostly 
unknown, underdiagnosed, and too often misdiagnosed with other similarly presenting diseases. Polygenic 
susceptibility combined with hormonal, microvascular, and lymphatic disorders may be partly responsi-
ble for its development. Furthermore, consistent information on lipedema pathophysiology is still lacking, 
and an etiological treatment is not yet available. Weight loss measures exhibit minimal effect on the abnormal 
body fat distribution, resulting in eating disorders, increased obesity risk, depression, and other psycho-
logical complaints. Surgical techniques, such as liposuction and excisional lipectomy, represent therapeutic 
options in selected cases. This review aims to outline current evidence regarding lipedema epidemiology, 
pathophysiology, clinical presentation, differential diagnosis, and management. Increased awareness and a 
better understanding of its clinical presentation and pathophysiology are warranted to enable clinicians to 
diagnose and treat affected patients at an earlier stage.
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Introduction
Lipedema is a chronic and progressive disease that can lead to considerable 
disability, daily functioning impairment, and psychosocial distress (1,2). 
It affects almost exclusively women, starting most often between puberty 
and the third decade of life (3). Lipedema involves abnormal deposition of 
subcutaneous adipose tissue, leading to a bilateral, disproportional volume 
increase of lower extremities and, in some cases, of arms. Fat deposition 
typically spares hands, feet, and trunk. Pathophysiological mechanisms of 
lipedema remain to be fully elucidated (4). Additionally, given the lack of 
consistent diagnostic criteria, its prevalence is difficult to establish, though 
it is thought to be common. Lipedema is in fact highly underdiagnosed by 
health care providers, being frequently misdiagnosed as obesity or lymph-
edema, diseases with which it shares several features. This review aims to 
outline current evidence to elucidate lipedema epidemiology, pathophys-
iology, clinical presentation, differential diagnosis, and management. The 
overall aim is to increase awareness among physicians and gradually offer 
patients a diagnosis and proper management.
Epidemiology
The literature has shown both scarce and conflicting data regarding the 
prevalence of lipedema. Child et al. (5) suggested a minimum value 
of 1:72.000 within the general population, though this may represent 
an underestimation of the real distribution of the disease. Lack of cur-
rent referrals is in fact responsible for the high rate of misdiagnosis 
of lipedema, which is frequently confused with other clinical entities, 
such as obesity and lymphedema. In a survey of 251 members of the 
Vascular Society of Great Britain and Ireland, only 46.2% of the con-
sultants were able to recognize the disease (6). Foldi et al. (7) reported 
percentages up to 11% among women and postpubertal girls admitted 
to their clinic for lower limb swelling. Moreover, Forner-Cordero et al. 
(1) reported that 18.8% of patients presenting with the same clinical 
presentation, between 2005 and 2012, actually suffered from lipedema. 
Similar percentages were found in a previous study on patients hos-
pitalized for lymphatic dysfunction (8) and in a more recent investi-
gation on patients presenting with suspected lymphedema in a French 
department of lymphology (9). These data refer to a selected popu-
lation and do not take into account the general population. Of note, 
a German cross-sectional study investigated lipedema prevalence in 62 
professional women (10). The researchers detected the disease in 39% 
of women (including all stages), and prevalence remained consistent 
(up to 9.7%) even for moderate to severe clinical presentation.
Lipedema affects mostly women and usually starts in puberty. Some 
reports refer to lipedema onset following pregnancy or even menopause 
(5). Men with lipedema have been mentioned in the literature only in 
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case reports, and male patients tend to have concomitant conditions 
associated with higher estrogen and lower relative testosterone lev-
els, such as male hypogonadism and liver disease (4,11,12). Children 
can also be affected, and 6.5% of infants with a supposed diagnosis 
of lymphedema actually suffered from lipedema in a 2011 report (13).
Pathophysiology
Little is known about lipedema pathophysiology, although some studies 
have suggested that polygenic susceptibility combined with hormonal, 
microvascular, and lymphatic disorders may be partly responsible for 
its development. Therefore, adipose tissue enlargement might not be 
the initial step in affected patients but rather the consequence of lymph-
angiopathy and/or microvascular dysfunction, starting a vicious cycle 
and resulting in persistent alterations in lymphatic and blood microcir-
culation. Hypothetical pathophysiological mechanisms responsible for 
lipedema development have been reviewed by Szél et al. (4). Several 
genes under the influence of estrogen, involved in vasculo- or lymphan-
gio-genesis, may play a role in endothelial dysfunction and lymphangi-
opathy. Additionally, it could be tempting to speculate that imbalanced 
estrogen-mediated mechanisms of weight control in the central ner-
vous system may be involved, at least partly, in lipedema pathogenesis, 
as 17β-estradiol’s actions in the brain are known to contribute to the 
regulation of body energy homeostasis, particularly in females (14). 
Estrogen also plays a pivotal role in region-specific sympathetic inner-
vation of subcutaneous adipose tissue. An intriguing hypothesis is that 
local inflammation of sensory nerves and adipose tissue dysfunction 
may act together and be responsible for the neuropathy typically found 
in this condition. Nonetheless, in light of the lack of high-quality sci-
entific research on lipedema pathophysiology, opinion and consensus 
largely dominate the literature, and some of the proposed mechanisms 
need to be taken carefully with a critical view.
Genetic background
In 60% of patients suffering from lipedema, genetic background with 
familial predisposition has been described (15). Studies have suggested 
that positive family history in affected patients ranges between 16% and 
64% (16). Furthermore, a clinical report on 330 family members found 
a possible autosomal dominant inheritance with incomplete disease 
penetrance, though genes involved have not been identified, and the 
unusually high prevalence of BMI consistent with obesity in the study 
raises questions about its applicability in the absence of obesity (5).
Lipedema was first described by Allen and Hines in 1940 as a condition 
characterized by “abnormally poor resistance to the passage of fluid 
into the tissue from the blood thus permitting oedema to occur” (17). 
This assertion suggests the presence of a connective tissue disorder with 
impaired adipose tissue elastic recoil, allowing fluid to collect rather 
than exit into lymphatic circulation (18). Williams syndrome, a genetic 
disease presenting with lipedema phenotype in both males and females, 
among other clinical features, is associated with loss of several genes, 
including ELN for elastin, which is an important component of connec-
tive tissue (19). Coherently with the hypothesis of an etiological role for 
loss of elasticity in lipedema, aortic stiffness develops in this condition 
(20) as well as in Williams syndrome (21). Research on both humans 
and animal models has suggested possible involvement of other genes. 
A study by Harvey et al. (22) showed that mice with functional inacti-
vation of a single allele of the homeobox gene PROX1 (which plays a 
critical role in embryonic development and functions as key regulatory 
protein in neurogenesis and heart, eye lens, pancreas, and lymphatic 
system development) displayed both defective lymphatic vasculature 
and subcutaneous and intra-abdominal fat accumulation (particularly 
around lymph nodes and in other regions rich in lymphoid tissue). In 
two animal models of hereditary lymphedema, mice carrying a vas-
cular endothelial growth factor receptor 3 (VEGFR3; also known as 
FMS-like tyrosine kinase 4 [Flt4]) heterozygous missense inactivat-
ing mutation, or expressing a soluble form of this receptor, developed 
hypoplastic dermal lymphatics and concomitant thickening of subcu-
taneous adipose tissue (23,24). An additional candidate in lipedema 
development may be PIT1 (encoding a transcription factor involved in 
the specification of the lactotrope, somatotrope, and thyrotrope pheno-
types in the developing anterior pituitary gland; also known as POU 
class 1 homebox 1 [POU1F1]). PIT1 mutation was found in a family 
in which short stature and leg swelling affected females through four 
generations (11). In line with this finding, González-Parra et al. (25) 
reported that modifications in circulating levels of sex hormones influ-
enced PIT1 expression. Along the same line, Foldi et al. (7) observed 
higher rates of lipedema after surgery for pituitary adenomas. Mutation 
of NSD1 (encoding a protein enhancing androgen receptor transactiva-
tion), responsible for Sotos syndrome (26), has been reported to cause 
estrogen-mediated formation of lipedema fat tissue. Finally, BMP2 
(encoding a secreted ligand of the transforming growth factor-beta 
superfamily of proteins and playing a central role in osteoblast differ-
entiation and cartilage development) is regulated by estrogen (27) and 
mediates inflammatory reaction with ensuing edema (28). BMP2 also 
induces adipogenesis through peroxisome proliferator-activated recep-
tor gamma (29); moreover, its administration in neurosurgery to stim-
ulate lumbar spine fusion was hypothesized to be responsible for acute 
epidural lipedema (30).
Hormonal influence
Because women are mainly concerned and the disease starts predom-
inantly at puberty, it would be tempting to speculate that lipedema’s 
pathophysiology is largely influenced by sex hormones. Estrogen is 
known to directly modulate lipid metabolism in white adipose tissue, 
mainly through estrogen receptor alpha and beta (ER-α and -β), and 
G-protein-coupled estrogen receptors (31). In light of the different dis-
tribution of androgenic and gynoid adiposity, effects of sex hormones 
are plausibly anatomical region specific. A study by Van Pelt et al. (32) 
showed that intravenous bolus of conjugated estrogen led to higher lev-
els of basal lipolysis in the abdominal region compared with the femo-
ral one. A subsequent study in premenopausal women with overweight 
or obesity found decreased ER-α and increased ER-β protein levels 
in the gluteal region compared with the abdominal one. Furthermore, 
researchers observed that the waist-hip ratio was inversely associated 
with gluteal ER-β protein levels and directly correlated to the gluteal 
ER-α–ER-β ratio (33). These findings may explain, at least partially, 
both the predilection of lipedema for  the female sex and the peculiar 
distribution of adiposity, suggesting that defective ER expression, 
distribution, and signaling pathway may be involved in lipedema 
development. Another crucial aspect that needs to be clarified is the low 
response of lipedema fat tissue to extreme diet and physical exercise (34). 
Hormonal influence should play a role. Indeed, estrogens act as central 
mediators for food intake and energy consumption in the hypothala-
mus. In particular, ER-α is expressed mainly by pro-opiomelanocor-
tin neurons of the arcuate nucleus (35), which plays a crucial role in 
food intake regulation through alpha-melanocyte-stimulating hormone 
secretion (36,37). Research has shown that brain-specific deletion of 
ER-α in female mice causes both hyperphagia and hypometabolism, 
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thus enhancing abdominal obesity (35,38). Further research is needed 
to elucidate whether an altered ER pattern and/or signaling pathway at 
a central level may explain typical resistance to weight loss in patients 
with lipedema.
Microangiopathy
Although not pathognomonic, and in spite of  a lack of high-quality 
scientific data, microangiopathy has been considered a typical his-
tological feature of lipedema by some researchers (7). This vascular 
alteration may be a consequence of the primary endothelial dysfunc-
tion through hypoxia mechanism with subsequent increased vascular 
fragility, similar to what was observed in patients with diabetic reti-
nopathy (39). Angiogenesis has several stimulators, including VEGF. 
In a study by Siems et al. (40), the authors found that average VEGF 
plasma levels were significantly above normal in patients undergoing 
shock-wave therapy for lipedema, thus suggesting a role for patholog-
ical angiogenesis in disease development. Increased oxidative stress 
was also described in patients with lipedema, displaying increased 
serum concentrations of malondialdehyde (a marker of lipid peroxi-
dation). Therefore, angiogenesis and increased capillary permeability 
may be consequences of imbalanced adipogenesis, leading to abnor-
mal fat expansion and subsequent tissue hypoxia. In line with this 
hypothesis, Suga et al. (41) carried out immunohistochemical anal-
yses in lipedema fat tissue and observed the presence of necrotizing 
adipocytes and infiltration of macrophages forming crown-like struc-
tures. Additionally, they described enhanced proliferation capacity of 
adipose-derived stem, progenitor, and stromal cells, likely promoting 
adipogenesis. Interestingly, a recent study by Al-Ghadban et al. (42) 
found that patients with lipedema and without concomitant obesity 
displayed hypertrophic adipocytes, increased numbers of macro-
phages and blood vessels, and dilation of capillaries in thigh fat com-
pared with healthy controls. Such findings suggest that inflammation 
and angiogenesis may occur independently of obesity in lipedema and 
support the role of an altered microcirculation in the manifestation of 
the disease.
Notably, increased free fatty acid levels may induce endothelial dys-
function and altered transendothelial transport (43,44), while leptin 
modulates angiogenesis under hypoxic conditions, having a direct 
effect on endothelium and VEGF expression (45,46).
The autoregulatory veno-arterial reflex (preventing edema forma-
tion) (47) should also be dysfunctional in patients with lipedema (7). 
Concerning this intriguing aspect, a pivotal role may be played by an 
overproduction of adipocyte-derived relaxing factor, released by peri-
adventitial adipose tissue and activating voltage-dependent potassium 
channels hyperpolarizing smooth muscle cell membranes (48).
Despite these interesting hypotheses, the existence and real contribu-
tion of microangiopathy in lipedema are still speculative and need to be 
confirmed by further and more exhaustive research.
Lymphangiopathy
Patients with lipedema display features of lymphedema, particularly 
in advanced stages (34). A study by Bilancini et al. (49) demonstrated 
an abnormal lymphoscintigraphic pattern with slowing of lymphatic 
flow in 12 lipedema-affected women, similar to what was observed 
in patients suffering from primary lymphedema. Amann-Vesti et 
al. (50) used fluorescence microlymphangiography and observed 
multiple microlymphatic aneurysms at the thigh, ankle region, or 
foot in 12 patients with lipedema. Enlarged lymphatic vessels with 
a beaded appearance were found by magnetic resonance lymphangi-
ography in affected participants (51). Functional and morphological 
abnormalities of lymphatic capillaries were also described by Foldi 
et al. (7), while Wollina et al. (52) showed podoplanin-negative sub-
cutaneous lymphatic vessels in two patients with lipo-lymphedema. 
Lastly, morphological studies using indirect  lymphangiography 
have documented typical changes, although not pathognomonic, in 
the form of flame-shaped contrast medium deposits in patients with 
lipedema (53).
Besides these findings, the exact role of lymphangiopathy in lipedema 
has not been yet determined. It is well known that adipocytes grow sig-
nificantly in the presence of lymphatic fluid (54). Nougues et al. (55) 
observed enhanced rabbit adipocyte differentiation and lipid accumula-
tion by adding mesenteric lymph and chylomicrons to culture medium. 
Other studies on animal models have demonstrated that lymphangiopa-
thy might actually enhance fat deposition (22,23).
Conversely, imbalanced and prolonged adiposity enlargement may also 
lead to microlymphatic disturbances, as observed by Blum et al. (56) 
in mice fed with a chronic high-fat diet. Expanding adipocytes pro-
duce some lymphangiogenic factors, such as VEGFC (57), which may 
induce lymphatic hyperplasia (58). Lastly, in hypoxic environments, 
hypoxia-inducible factor 1 enhances fibrosis (59), thus potentially com-
promising lymphatic drainage in dysfunctional adipose tissue.
Taking into account these findings, research is still needed to clarify 
whether a persistent and progressive damage of the microlymphatic 
vessels because of adipose tissue expansion (16), rather than a primary 
lymphatic defect, may be responsible for the lipo-lymphedema state.
Adipogenesis
As already mentioned, previous research has reported enhanced adi-
pose stem cell proliferation in patients with lipedema, which is likely 
responsible for the massive adipose tissue enlargement typically found 
in this condition (41). More recently, stromal vascular fraction obtained 
by liposuction from 52 affected women revealed a significant increase 
in adipose stem cell number (60). Interestingly, approximately half 
of these cells seemed to originate from perivascular cells, while 20% 
of them showed characteristics of pericyte-like cells. These findings 
are of particular relevance, as Li et al. (61) previously demonstrated 
that perivascular-derived cells from adipose tissue exhibited very low 
adipogenic differentiation potential compared with the  preadipocyte 
subpopulation. Likewise, Hu et al. (62) found that a subpopulation of 
these latter cells also showed lower adipogenic potential. In line with 
these results, in vitro adipogenic differentiation potential assessed by 
the degree of lipid droplet accumulation on adipogenic induction was 
significantly reduced in patients with lipedema compared with healthy 
participants (60).
Intriguingly, several studies have demonstrated impaired preadipocyte 
differentiation in patients with obesity (63). Several hypotheses have 
been proposed to explain why some patients are unable to expand their 
adipose tissue in a healthy manner. Like other organs and tissues, it has 
been supposed that adipose tissue growth must be accompanied by a par-
allel expansion of its vascular network. Notably, several researchers have 
demonstrated a capillary reduction in the subcutaneous adipose tissue 
of patients with obesity (64,65). This phenomenon may lead to hypoxia 
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and impaired secretion of adipokines, thus contributing to adipose tissue 
low-grade inflammation, which may in turn affect  the adipogenic pro-
gram. However, whether these series of events are shared by obesity and 
lipedema remains unclear.
Clinical Presentation and Cardiovascular 
Risk
Localization of lipedema fat tissue is of gynoid type, with typical 
involvement of the hips, buttocks, thighs, and lower legs, resulting in a dis-
proportion between the upper and lower body (i.e., a waist-hip ratio < 1). 
Distinct features of lipedema are a sharp separation between normal and 
abnormal tissue at the ankle (“cuff sign”) and significant disproportion 
in circumference between the hips and waist (“riding breeches”). Based 
on distribution, five types of lipedema have been described (Figure 1A). 
In type I, lipedema fat tissue accumulates around the hips and buttocks; 
in type II, accumulation involves the area from hips to knees; and in 
type III, a hip to ankle phenotype is observed. Approximately 80% 
of affected women have an additional involvement of arms (type IV), 
while it is rare to find fat dominating the calf region only (type V). In 
terms of severity, four stages have been described (Figure 1B). In stage 
1, skin may be smooth and soft, but the underlying hypodermis is 
enlarged; in stage 2, skin may be indented over palpable pearl-sized nod-
ules (“peau d’orange”); and stage 3 is characterized by folds and divots 
over deforming, larger fat masses, frequently associated with functional 
limitations. The development of concomitant lymphedema defines the 
stage 4 (18). The lipo-lymphedema, or lipedema stage 4, is usually 
Figure 1 (A) Types and (B) stages of lipedema.
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the result of a long-term evolution of the disease from subclinical to 
clinically manifested lymphedema, thus representing a more advanced 
stage in most cases. Besides edema of the feet, with a pathognomonic 
positive Stemmer sign, stage 4 may be accompanied by other common 
features of advanced lymphedema, such as cellulitis or papillomato-
sis. Overall, disease progression is heterogeneous and highly variable 
from one individual to the other. Indeed, some women develop minor 
lipedema, stabilizing over time, while others exhibit gradual disease 
progression with sudden stress-induced exacerbation (i.e., pregnancy 
or surgery) (16).
The most common complaints of patients are easy bruising and mod-
erate to severe pain at digital pressure on affected limbs. Most individ-
uals also experience spontaneous pain. Orthostatic edema is another 
cardinal sign, which may be responsible for leg heaviness, fatigue, and 
discomfort. Swelling and pain worsen during warm weather and exer-
cise, and they are not alleviated by limb elevation. Conversely, pain is 
significantly reduced by lipoaspiration (66). In a single case report (67), 
the presence of pain was attributed either to mechanical forces or to bio-
chemical effects on sympathetic nerve fibers, with inflammation play-
ing a leading role in this scenario. Microangiopathy with inappropriate 
blood supply to peripheral nerves may also contribute to protopathic 
sensibility disturbance (67).
Women with lipedema are at an increased risk for developing mor-
bid obesity, and obesity itself is regarded as a risk factor for lipedema 
(68). Despite overexercise and extreme dieting, weight loss measures 
exhibit minimal effect on the abnormal body fat distribution in patients 
with lipedema. This often results in eating disorders, increased risk for 
depression, and other psychological complaints, which are commonly 
reported in this condition (34).
Excessive fat on the buttocks, hips, thighs, and lower legs also impacts 
the gait of patients with consequent malalignment of the mechanical leg 
axis, thus resulting in joint stress (69). This often provokes knee val-
gus osteoarthritis, antalgic gait, and feet overpronation. Hypermobility, 
which appears to be prevalent in the population with lipedema, can fur-
ther enhance these complications (70). Additionally, skin lesions, mac-
eration, and infection may occur because of bulging tissue and deep 
skin folds (71).
Interestingly, patients with lipedema display a less severe cardiovas-
cular profile (18). Pinnick et al. (72) showed that gynoid fat negatively 
correlated with insulin resistance after total fat adjustment, whereas the 
opposite was found for abdominal fat. Furthermore, a previous study 
by Mekki et al. (73) found lower fasting triglyceride-rich lipoprotein, 
lower triglyceride levels, and smaller chylomicron particle size after a 
mixed test meal providing 40 g of triglycerides in women with a gynoid 
fat distribution compared with those with an android distribution. These 
findings suggest that lipedema fat tissue, which has typically a gynoid 
distribution, may have protective effects against metabolic dysfunction; 
however, the authors did not specify whether some of the included 
patients had lipedema.
Low prevalence of diabetes has also been described in patients suf-
fering from lipedema despite an average BMI of 39 ± 12 kg/m2 (70). 
Additionally, a recent study on 46 affected patients found that the 
majority of them had a normal lipid profile, while only 11.7% had total 
cholesterol ≥ 240 mg/dL (18), compared with higher percentages (up to 
33.5%) in the general female population.
The same study found that less than 30% of women with stages 2 or 
3 lipedema had hypertension, which was even absent in patients with 
stage 1. Interestingly, national data have suggested hypertension rates 
of 32.4% in women of any BMI aged 40 to 59 years and even higher 
hypertension rates (up to 60%) in Caucasian women with obesity 
and a mean age of 63 (18). Nonetheless, patients with lipedema were 
shown to develop aortic stiffness in one study (20), which seems to 
contradict these findings. Geographic differences of women included 
in the these studies may partly explain such apparently contradictory 
findings. Further research is needed to clarify these aspects.
Assessment and Diagnosis
The diagnosis of lipedema is based on clinical evidence and exclusion 
criteria. In 1951, Wold et al. (17) proposed a list of six diagnostic crite-
ria, which were extended in 2017 in the first Dutch guidelines, based on 
clinical experience and literature evidence (74). In Table 1, we propose 
a slightly modified version of the list recently published by Halk and 
Damstra (74).
TABLE 1 Diagnostic criteria of lipedema
Medical history (A) (criteria of Wold et al. (17))
A 1 Disproportionate body fat distribution
2 No or limited influence of weight loss on fat 
distribution
3 Limb pain and bruising
4 Increased sensitivity to touch or limb fatigue
5 Nonpitting edema
6 No reduction of pain or discomfort with limb lift
Physical examination (B, C, D, E)
B Proximal part of the lower limb
1 Disproportionate fat distribution
2 Circumferentially thickened cutaneous fat
C Distal part of the lower limb
1 Proximal thickening of subcutaneous fat
2 Distal thickening of subcutaneous fat, accompa-
nied by slender instep (cuff sign)
D Proximal part of the arm
1 Significantly thickened subcutaneous fat in com-
parison with vicinity
2 Sudden stop at elbow
E Distal part of the arm
Thickened subcutaneous fat, accompanied by 
slender back of hand (cuff sign)
Extra criteria
F 1 Pain when applying bimanual palpation
2 Distal fat tissue tendrils of the knee (popliteus)
Modified from Halk and Damstra (74).
Diagnosis is highly probable when present: A (1 to 6) + (B [1 + 2] or C [1 + 2] or D [1 + 2] 
or E).
In the absence of at most two of these criteria (A to E), the presence of the extra crite-
ria F(1) or F(2) also support the diagnosis.
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To correctly follow up patients, Reich-Schupke et al. (71) recom-
mended using clinical parameters such as daily activity index, weight, 
BMI, waist-hip ratio, waist-height ratio, and limb measurements of 
circumference and volume (e.g., perometer). Interestingly, dual- 
energy x-ray absorptiometry, measuring regional body composition, 
provides quantification and distribution information about total and 
regional fat, lean, and bone mass, thus representing a useful tool 
for diagnosis, staging, and follow-up (75,76). In a study by Dietzel 
et al. (75) comparing patients with lipedema and obesity, the amount 
of fat in the leg and in the gynoid region was significantly higher in 
patients with lipedema once adjusted for BMI. The optimal cutoff 
value for leg fat mass per BMI to identify lipedema was considered to 
be 0.46. This reference may be particularly helpful for a differential 
diagnosis in otherwise doubtful cases (75). Figure 2 shows a poten-
tial diagnostic and therapeutic work-up for patients with suspected 
lipedema.
The differential diagnosis of lipedema includes conditions present-
ing with swelling or excessive adiposity of lower limbs, mainly 
represented by lymphedema and obesity (Table 2). In cases of more 
advanced edema, other classical causes (i.e., chronic venous insuffi-
ciency, idiopathic cyclic edema, edema because of cardiac, hepatic, 
or renal disease, myxedema, and orthostatic edema) should also be 
considered.
In lymphedema, the skin is usually altered and thickened, while it 
remains relatively normal in lipedema. Nevertheless, distinguishing 
lipedema from lymphedema may be difficult because the two condi-
tions may coexist in advanced stages of disease. Compared with lymph-
edema, digital pressure typically induces pain in patients with lipedema. 
Lymphoscintigraphy and green indocyanine lymphofluoroscopy may 
show impaired lymphatic flow in the affected extremity of patients with 
lipedema. Impaired lymphatic flow in affected patients is generally 
less severe than in patients with lymphedema, and imaging may show 
lymphatic dysfunction that is not yet clinically evident (77,78). In light 
of these findings, imaging techniques may be considered as a useful 
tool when diagnosis is doubtful or for lipedema staging. Magnetic res-
onance imaging, computed tomography, and high-resolution cutaneous 
ultrasonography have been also used to differentiate lymphedema from 
lipedema, although these are seldom applied in the clinic (79,80).
Recognizing lipedema among all conditions characterized by excess 
adiposity in the  lower limbs is particularly challenging. BMI may 
be helpful in differentiating it from obesity, though patients with 
lipedema may develop obesity at later stages. In a study by Child 
et al. (5), BMI of the majority of patients with lipedema was consistently 
within the obesity class II (BMI = 35-39.99, 27%) or class III (BMI > 40, 
50%) range. A distinctive feature of lipedema consists of high resis-
tance to lower limb volume reduction following overexercise, extreme 
dieting, and even bariatric surgery (81). Other characteristic hallmarks 
are easy bruising, typical anatomical fat distribution, and presence of 
the “cuff sign.”
Dercum disease (adiposis dolorosa) is a clinical condition that partly 
overlaps with lipedema, as the two share cardinal features such as spon-
taneous or palpation-induced pain and bruising. At its onset, Dercum 
disease is characterized by multiple painful lipomas with possible pro-
gression into circumscribed or general diffuse fatty deposition. It is 
usually accompanied by recurrent headache and depression, which are 
less frequently described in lipedema (82). Although considered a post-
menopausal condition by some researchers, Dercum disease has also 
been described in premenopausal women and even in men (70). Despite 
some apparent differences, sharp discrimination with lipedema may be 
complex in clinical practice, and particular awareness on Dercum dis-
ease is needed to avoid misdiagnosis.
Another common condition that can be confused with lipedema is 
chronic venous disease (83). Classic hallmarks of this entity include pit-
ting edema, improvement of symptoms and swelling with leg elevation, 
and, in advanced stages, skin changes with typical brown coloration 
(dermite ocra), white scars (atrophie blanche), and ulcers. Notably, 
swelling also involves the ankles and feet in these patients, with a typi-
cal negative Stemmer sign. Varicose veins are also frequently observed 
in lipedema patients and cannot be used for differential diagnosis (5,17).
Treatment
Given the lack of sufficient information regarding pathophysiology 
and the relatively scarce experience in terms of management, therapeu-
tic options for lipedema remain limited (3,4,41). Main goals include 
symptom reduction, functional limitation amelioration, and preven-
tion of disease progression. In the absence of an etiological treatment, 
therapeutic approaches also aim at impacting factors negatively influ-
encing lipedema progression, such as obesity, lymphedema, venous 
insufficiency, and decreased physical activity (84). Management of 
the patient’s expectations through education is essential. Psychological 
support is recommended (16,85,86). Surgical approaches may be lim-
ited to selected cases.
Conservative treatment
An active lifestyle should be encouraged, and a multidisciplinary 
approach to obesity, including dietary modification, is important to 
consider (84). Although dietetic strategies cannot prevent the dispropor-
tional fat distribution, they may reduce local inflammation, thus amelio-
rating symptoms and improving general well-being and overall health 
(83). Lifestyle changes cannot reduce fat deposition; however, obesity 
prevention is crucial because further adipose tissue deposition scarcely 
responds to diet and exercise. Notably, there is no specific diet for 
lipedema. However, because insulin promotes lipogenesis and insulin 
resistance worsens edema formation, a diet avoiding glycemic and 
insulin peaks and allowing adequate intervals between meals (i.e., isogly-
cemic diet) may be desirable. Weight loss should not be achieved at the 
expense of muscle mass (87-89). Aquatic physical activity seems to be 
particularly beneficial in patients with lipedema because water pressure 
promotes lymph drainage and buoyancy reduces the load on the joints 
of lower limbs, decreasing the risk of future orthopedic complications.
To ameliorate therapeutic outcomes, the use of compression garments 
represents another milestone of conservative treatment and is often able 
to reduce the pain and discomfort of affected limbs. In patients with 
lipo-lymphedema, complex decongestive lymphatic therapy (CDP) may 
be also useful (1). CDP consists of manual lymph drainage associated 
with multilayered and multicomponent compression bandaging, metic-
ulous skin care, and physical exercise. In selected patients, combination 
with intermittent pneumatic compression has been shown to improve 
venous flow and decrease lymph production (90). In a clinical study 
comparing CDP with and without intermittent pneumatic compression, 
researchers found significant lower limb volume reduction with both 
approaches (6.2% and 8.9%, respectively; P < 0.05) (91). According to 
a recent Canadian study (92), treatment of bilateral lymphedema can be 
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Figure 2 Algorithm for work-up in patients presenting with suspected lipedema. DLT, decongestive lymphatic therapy; CDP, complex 
decongestive physiotherapy; WHR, waist-hip ratio; WHtR: waist-height ratio; DXA, dual-energy x-ray absorptiometry; CT, computed 
tomography; MRI, magnetic resonance imaging.
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significantly more time-consuming, costly, and challenging than that 
of unilateral limbs; this is also true for patients with lipo-lymphedema.
Pharmacological options, including beta-adrenergic agonists, cortico-
steroids, diuretics, flavonoids, and selenium, have also been suggested 
(34,93), although their real efficacy in this condition remains to be 
elucidated.
Surgical treatment
For patients with minimal or no improvement following conserva-
tive approaches, the following two surgical options may be consid-
ered: liposuction and lipectomy (94). Notably, techniques employed 
in lipedema patients differ from those adopted for cosmetic purposes 
(15,66,95). Early procedures, such as dry liposuction, carry an inac-
ceptable risk of lymphatics damage in patients suffering from lipedema 
(96). Following introduction of tumescent local anesthesia (TLA), 
super-TLA, and vibrating cannulas, this risk has considerably 
decreased. Several investigations have shown that TLA is highly effec-
tive in terms of both cosmetic and functional outcomes. Schmeller et al. 
(15) described an average reduction of 9,846 mL of subcutaneous fatty 
tissue after treatment, with an additional amelioration of sensitivity to 
pressure, edema, bruising, functional limitation, and cosmetic complaint 
(P < 0.001). Moreover, no serious complication occurred following the 
procedure, with wound infection rates of 1.4% and bleeding rates of 
0.3% (15). Very recently, Wollina et al. (97) reported on 111 patients 
mostly with advanced lipedema treated by microcannular liposuction in 
tumescent anesthesia between 2007 and 2018. They described a median 
total amount of lipoaspirate of 4,700 mL, a median reduction of limb 
circumference of 6 cm, and a median pain level lowering from 7.8 to 
2.2 at the end of treatment as well as improved mobility and bruising. 
Serious adverse events were observed in 1.2% of procedures, with 
infection and bleeding rates being 0% and 0.3%, respectively (97).
Although some studies have reported better outcomes in the early stages 
of lipedema compared with advanced ones (15), consistent criteria to 
identify the ideal timing or patient characteristics for liposuction are 
lacking. TLA requires specialized skills and should be performed only 
in specialized centers. In advanced lipedema stages, multiple sessions 
are frequently necessary to remove larger amounts of adipose tissue and 
prevent recurrent fat deposition. Unfortunately, lipedema surgical treat-
ments are still too often not reimbursed by health insurance companies, 
thus representing an expensive option for the overwhelming majority of 
patients (74). In addition, despite several promising short-term results, 
only a few studies have evaluated the long-term efficacy of TLA for 
lipedema treatment (15,98,99). Future research with longer-term out-
comes will help support the role of liposuction in the management of 
such a condition.
In complicated and advanced cases of lipedema with severe mechanical 
limitations, a more invasive surgical approach consisting of excision of 
large localized deposits of lipedema fat tissue (“lumps”) as a debulking 
procedure (lumpectomy) may be considered (52). Nevertheless, it has 
to be noted that this technique may be associated with the development 
of secondary lymphedema (100).
Conclusion
A call to action  for increasing awareness about this widespread and 
too often misdiagnosed disease is urgently needed. Health care pro-
viders should be prompted to diagnose lipedema as early as possible 
and to offer patients the best management solutions. Best management 
includes a multidisciplinary approach, involving vascular medicine 
specialists, plastic surgeons, obesity and endocrinology specialists, and 
physiotherapists. In parallel, there is a strong need to conduct specific 
studies to better understand  the pathophysiology of lipedema  and to   
design specific therapeutic strategies. O
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